When Sarkosyl-insoluble fractions of tau from AD, PSP and CBD brains were analyzed by immunoblotting with T46 and RD4, we noticed a lower immunoreactivity of RD4 with abnormal tau in AD compared to that in both PSP and CBD (Figure 1a,b). This evidence concerns the gene MAPT and Alzheimer disease.